175 related articles for article (PubMed ID: 15342377)
21. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
22. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
Crowe DL; Sinha UK
Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
[TBL] [Abstract][Full Text] [Related]
23. RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age.
Olasz J; Juhász A; Remenár E; Engi H; Bak M; Csuka O; Kásler M
Oncol Rep; 2007 Jul; 18(1):105-12. PubMed ID: 17549354
[TBL] [Abstract][Full Text] [Related]
24. Methylation and intratumoural heterogeneity of 14-3-3 sigma in oral cancer.
Bhawal UK; Tsukinoki K; Sasahira T; Sato F; Mori Y; Muto N; Sugiyama M; Kuniyasu H
Oncol Rep; 2007 Oct; 18(4):817-24. PubMed ID: 17786341
[TBL] [Abstract][Full Text] [Related]
25. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma.
Bennett KL; Hackanson B; Smith LT; Morrison CD; Lang JC; Schuller DE; Weber F; Eng C; Plass C
Cancer Res; 2007 May; 67(10):4657-64. PubMed ID: 17510391
[TBL] [Abstract][Full Text] [Related]
26. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
27. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
[TBL] [Abstract][Full Text] [Related]
28. LHX6 is a sensitive methylation marker in head and neck carcinomas.
Estécio MR; Youssef EM; Rahal P; Fukuyama EE; Góis-Filho JF; Maniglia JV; Goloni-Bertollo EM; Issa JP; Tajara EH
Oncogene; 2006 Aug; 25(36):5018-26. PubMed ID: 16732332
[TBL] [Abstract][Full Text] [Related]
29. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
30. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy.
Frigola J; Muñoz M; Clark SJ; Moreno V; Capellà G; Peinado MA
Oncogene; 2005 Nov; 24(49):7320-6. PubMed ID: 16007128
[TBL] [Abstract][Full Text] [Related]
31. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation.
Takada H; Imoto I; Tsuda H; Nakanishi Y; Ichikura T; Mochizuki H; Mitsufuji S; Hosoda F; Hirohashi S; Ohki M; Inazawa J
Oncogene; 2005 Dec; 24(54):8051-60. PubMed ID: 16103878
[TBL] [Abstract][Full Text] [Related]
32. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
[TBL] [Abstract][Full Text] [Related]
33. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
34. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
[TBL] [Abstract][Full Text] [Related]
36. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region.
Hauser U; Balz V; Carey TE; Grénman R; Van Lierop A; Scheckenbach K; Bier H
Head Neck; 2002 Sep; 24(9):868-73. PubMed ID: 12211051
[TBL] [Abstract][Full Text] [Related]
37. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
[TBL] [Abstract][Full Text] [Related]
38. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression.
Kawamura K; Izumi H; Ma Z; Ikeda R; Moriyama M; Tanaka T; Nojima T; Levin LS; Fujikawa-Yamamoto K; Suzuki K; Fukasawa K
Cancer Res; 2004 Jul; 64(14):4800-9. PubMed ID: 15256449
[TBL] [Abstract][Full Text] [Related]
39. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer.
Kim MS; Yamashita K; Baek JH; Park HL; Carvalho AL; Osada M; Hoque MO; Upadhyay S; Mori M; Moon C; Sidransky D
Cancer Res; 2006 Apr; 66(7):3409-18. PubMed ID: 16585162
[TBL] [Abstract][Full Text] [Related]
40. Analysis of tumor suppressor p53 status in head and neck squamous cell carcinoma.
Smardova J; Ksicova K; Binkova H; Krpensky A; Pavlova S; Rottenberg J; Koukalova H
Oncol Rep; 2004 Apr; 11(4):923-9. PubMed ID: 15010896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
